BAM
TNYA icon

Belpointe Asset Management’s Tenaya Therapeutics TNYA Stock Holding History

Belpointe Asset Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,509
Closed -$26K – 1233
2026
Q1 		$26K Buy
+37,509
New +$27.7K ﹤0.01% 1060

Other funds holding TNYA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Belpointe Asset Management's TNYA Position: Q2 2026 in Review

Belpointe Asset Management sold out of Tenaya Therapeutics (TNYA) in Q2 2026, closing a stake of 37,509 shares — an estimated $26K sold.

Belpointe Asset Management first reported a position in TNYA in Q1 2026 and held it in 1 quarter. The position peaked at $26K in Q1 2026. 101 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

  • Belpointe Asset Management reported no remaining Tenaya Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Belpointe Asset Management sold 37,509 Tenaya Therapeutics shares in Q2 2026, an estimated $26K.
  • Belpointe Asset Management first reported a position in Tenaya Therapeutics in Q1 2026 and held it in 1 quarter.
  • Belpointe Asset Management's Tenaya Therapeutics position peaked at $26K in Q1 2026.
  • 101 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.